Search - tctmd.com

Displaying 1 - 20 of 115

Sort: Relevancy | Date

News Industry News

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

October 29, 2025

Presentation TCT 2025

Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial

Presenter: Patrick W. Serruys

October 28, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

Podcast TCTMD Talking Points

The CLEAR SYNERGY (OASIS 9) Trial

September 17, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2024

Shelley Wood

December 03, 2024

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

Presentation AHA 2024

Routine spironolactone in Acute Myocardial Infarction, results from the CLEAR SYNERGY OASIS 9 trial

Presenter: Sanjit S Jolly

November 17, 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2024

Shelley Wood

November 01, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

Presentation TCT 2024

CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine Versus Placebo and Spironolactone Versus Placebo in Patients With Myocardial Infarction

Presenter: Sanjit Jolly

October 29, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Conference News TCT 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

L.A. McKeown

October 31, 2023

News Conference News SCAI 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

L.A. McKeown

May 31, 2023

News Conference News STS 2023

Surgeons ‘Implore’ Colleagues to Learn TEER Lest They Become ‘Dinosaurs’

Yael L. Maxwell

February 02, 2023

News Daily News

Inequities in Mitral, Tricuspid Trials Have Implications Across CV Research

Yael L. Maxwell

December 12, 2022

Presentation TCT 2022

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

Presenter: Yoshinobu Onuma

September 17, 2022

Advertisement

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial

ACC: It’s Time for Clinicians to Address Inflammation in CVD

The CLEAR SYNERGY (OASIS 9) Trial

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Top Coronary Artery Disease News in 2024

TCTMD’s Top 10 Most Popular Stories for November 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Routine spironolactone in Acute Myocardial Infarction, results from the CLEAR SYNERGY OASIS 9 trial

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

TCTMD’s Top 10 Most Popular Stories for October 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine Versus Placebo and Spironolactone Versus Placebo in Patients With Myocardial Infarction

What’s Going to Be Big at TCT 2024?

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

Surgeons ‘Implore’ Colleagues to Learn TEER Lest They Become ‘Dinosaurs’

Inequities in Mitral, Tricuspid Trials Have Implications Across CV Research

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content